RedX Pharma PLC (LON:REDX) CEO Lisa Anson has hailed “strong progress” with the company’s pipeline of drug candidates in the first half of its current year. Anson tells Proactive London about RedX's two clinical assets in progress, as well as fleshing out details on working partnership benefits. In its latest results, RedX said it had successfully completed dosing of the first four patient cohorts in a Phase 1 clinical trial of its lead oncology asset, adding that post-period it has also initiated a second clinical programme for a selective inhibitor for development in idiopathic pulmonary fibrosis and possibly other fibrotic conditions.
RedX Pharma drug candidate pipeline underpins strong first half progress
